Fig. 7: Inhibition of NFAT5 K668 methylation improves TMZ efficacy in vivo.
From: Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma
a The representative bioluminescent images of Balb/c nude mice harboring tumors derived from NFAT5 WT or K668R mutant-transfected U87/EGFRvIII cells treated with TMZ therapy every week (n = 4 mice per group). b Kaplan–Meier survival curves of mice shown in (a), n = 7 mice/group. c Representative images of IF staining of O6-MetG in tumors derived from NFAT5 WT or K668R mutant-transfected U87/EGFRvIII cells treated with TMZ therapy. n = 5 randomly captured field of view. Scale bar: 50 µm. d The representative bioluminescence images of mice bearing tumors from U87/EGFRvIII cells treated with TMZ, DZNep, alone or in combination (n = 4 mice per group). e Representative H&E-stained coronal brain sections of mice from experiment shown in (d). Scale bar: 100μm. f Survival of mice injected with TMZ, DZNep alone or in combination, n = 7 mice/group. g IF staining of O6-MetG, γH2AX and cleaved-caspase3 in tumors derived from U87/EGFRvIII cells treated with TMZ, DZNep, alone or in combination. n = 5 randomly captured field of view. Scale bar: 50 µm. h IHC staining of NFAT5 and Me3-NFAT5 K668 expression in the tumors from experiment shown in (d). Scale bar: 100μm. i Combination of TMZ and DZNep impaired the interaction between NFAT5 and EZH2 as well as IMB1. a–i n = 2 independent experiments; Significance was calculated by (a, d) ANOVA of repeated measurement data; (b, f) by Log-rank (Mantel–Cox) test; Data were presented as mean ± standard deviation. Marker unit for Western blots is kDa. Source data are provided as a Source Data file.
